Common-Size Income Statement
Paying user area
Try for free
Amgen Inc. pages available for free this week:
- Balance Sheet: Assets
- Analysis of Solvency Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Common Stock Valuation Ratios
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Return on Equity (ROE) since 2005
- Debt to Equity since 2005
- Price to Sales (P/S) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Amgen Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Amgen Inc., common-size consolidated income statement
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
| Income statement item | Description | The company |
|---|---|---|
| Operating income | The net result for the period of deducting operating expenses from operating revenues. | Amgen Inc. operating income as a percentage of product sales increased from 2021 to 2022 but then decreased significantly from 2022 to 2023. |
| Income before income taxes | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Amgen Inc. income before income taxes as a percentage of product sales increased from 2021 to 2022 but then slightly decreased from 2022 to 2023. |
| Net income | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Amgen Inc. net income as a percentage of product sales increased from 2021 to 2022 but then slightly decreased from 2022 to 2023 not reaching 2021 level. |